GLP-3 Reta 50mg / Reta 30mg

Retatrutide (GLP-3) 50mg / 30mg Research Peptide

GLP-3 Reta 50mg A First-in-Class Triple Hormone Receptor Agonist

Retatrutide is an investigational synthetic peptide and the first triple hormone receptor agonist to reach Phase 3 clinical trials. It is an emerging next-generation compound designed to activate three naturally occurring metabolic pathways—GIP, GLP-1, and glucagon—simultaneously.

This triple agonist mechanism distinguishes retatrutide from earlier generations of metabolic research compounds: GLP-3 Reta 50mg 

• First Generation: Single GLP-1 receptor agonists (e.g., semaglutide)

• Second Generation: Dual GLP-1/GIP receptor agonists (e.g., tirzepatide)

• Third Generation: Triple GLP-1/GIP/glucagon receptor agonists (retatrutide)

Mechanism of Action: Triple Receptor Agonism

Retatrutide functions as a potent agonist at three key metabolic receptors:

By engaging all three pathways, retatrutide aims to reduce food intake, improve metabolic control, and increase calorie burning—offering a multi-targeted approach to metabolic research.

Key Research Findings GLP-3 Reta 50mg 

Retatrutide has demonstrated significant efficacy across multiple Phase 3 clinical trials:

• TRIUMPH-1 (Obesity): At 80 weeks, participants taking retatrutide 12 mg lost an average of 70.3 lbs (28.3%). 65.3% of participants achieved a BMI below the obesity threshold.

• TRIUMPH-4 (Obesity & Knee Osteoarthritis): The 12 mg dose delivered 28.7% average weight loss (~71 lbs) at 68 weeks, with significant improvements in pain and physical function. Dysesthesia (abnormal skin sensations) was reported in 20.9% of participants on the 12 mg dose versus 0.7% on placebo.

• TRANSCEND-T2D-1 (Type 2 Diabetes): Participants experienced up to a 2% reduction in A1C and 15.3% body weight loss (average 36.6 lbs) at 40 weeks. Gastrointestinal side effects were the most common, generally mild to moderate, and subsided over time.

• TRIUMPH-2 (Obesity & Type 2 Diabetes): The 12 mg dose produced 20.8% weight loss (~49.6 lbs) at 80 weeks with A1C reductions up to 1.6%.

• TRIUMPH-3 (Obesity & CVD): Adults with severe obesity and established CVD achieved 22.6% weight loss (~55.8 lbs) at 80 weeks on the 12 mg dose, with meaningful reductions in CV risk factors.

Product Specifications GLP-3 Reta 50mg 

Critical Regulatory and Safety Information

Retatrutide is not FDA-approved. It is an investigational drug in Phase 3 clinical trials and is not legally available for human use outside of clinical trials.

Regulatory Status

• Not FDA-Approved: Eli Lilly has announced plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027.

• Compounding Warning: The FDA has issued explicit warnings that compounded retatrutide products are unapproved new drugs and misbranded. Retatrutide is not eligible for compounding under current FDA exemptions.

• Legitimate Access: The only legitimate way to access retatrutide today is enrollment in a TRIUMPH clinical trial.

Warnings and Contraindications

• GLP-3 is a Misnomer: Humans produce GLP-1 and GLP-2; there is no natural GLP-3 hormone. The GLP-3 label is an informal nickname that circulates online and is not used by Eli Lilly, the FDA, or peer-reviewed journals.

• Dysesthesia: A notable adverse effect—abnormal skin sensations such as tingling or burning—was reported in up to 20.9% of participants on the 12 mg dose in TRIUMPH-4.

• Gastrointestinal Effects: Common side effects include nausea, diarrhea, vomiting, constipation, and decreased appetite. These are consistent with other GLP-1 class compounds.

• Heart Rate Elevation: Dose-dependent increases in heart rate have been observed with glucagon agonism.

• Research Product Risks: Products sold online as retatrutide peptide are unregulated research chemicals. Purity, dosage accuracy, and sterility are unverified.